» Articles » PMID: 34062483

Epidemiology of Cutaneous Melanoma and Keratinocyte Cancer in White Populations 1943-2036

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2021 Jun 1
PMID 34062483
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Cutaneous melanoma (CM) and keratinocyte cancer (KC) cause considerable morbidity and mortality. We analysed long-term trends of CM and KC in different white populations.

Material And Methods: Age-standardised (European Standard Population 2013) incidence and mortality rates (ASIR, ASMR) of CM were extracted from cancer registries in Denmark, New Zealand and the US SEER-Database. ASIRs of KC were sourced from registries of the German federal states Saarland and Schleswig-Holstein, and from Scotland. Age-period-cohort models were used to project melanoma incidence trends.

Results: In Denmark between 1943 and 2016, melanoma ASIR increased from 1.1 to 46.5 in males, and from 1.0 to 48.5 in females, estimated to reach 60.0 and 73.1 in males and females by 2036. Melanoma mortality in Denmark (1951-2016) increased from 1.4 to 6.7 (males) and 1.2 to 3.7 (females). In New Zealand between 1948 and 2016, ASIR increased from 2.7 to 81.0 (males) and from 3.8 to 54.7 (females), slight declines are estimated by 2036 for both genders. Melanoma mortality increased six-fold in New Zealand males between 1950 and 2016; smaller increases were observed in females. We observed three- to four-fold increases in melanoma incidence in US whites, predicted to rise to 56.1 and 36.2 in males and females until 2036. Melanoma mortality also increased among US whites between 1970 and 2017, female melanoma mortality remained stable. Similar trends are shown for KC.

Conclusions: In white populations, incidence of CM and KC significantly increased. CM incidence continues to rise in the short term but is predicted to decline in future.

Citing Articles

Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990-2021.

Zhou L, Zhong Y, Han L, Xie Y, Wan M Sci Rep. 2025; 15(1):5996.

PMID: 39966563 PMC: 11836239. DOI: 10.1038/s41598-025-90485-3.


Patient Satisfaction With Surgery of Basal Cell Carcinoma: Keep It Safe and Simple.

Behnejad R, Herr R, Koliakou E, Zahn A, Peitsch W Cureus. 2025; 17(1):e76891.

PMID: 39902003 PMC: 11788872. DOI: 10.7759/cureus.76891.


Individualized Neoantigen-Directed Melanoma Therapy.

Khaddour K, Buchbinder E Am J Clin Dermatol. 2025; 26(2):225-235.

PMID: 39875711 DOI: 10.1007/s40257-025-00920-4.


User and Developer Views on Using AI Technologies to Facilitate the Early Detection of Skin Cancers in Primary Care Settings: Qualitative Semistructured Interview Study.

Jones O, Calanzani N, Scott S, Matin R, Emery J, Walter F JMIR Cancer. 2025; 11:e60653.

PMID: 39874580 PMC: 11815299. DOI: 10.2196/60653.


AI-Driven Enhancement of Skin Cancer Diagnosis: A Two-Stage Voting Ensemble Approach Using Dermoscopic Data.

Chiu T, Li Y, Chi I, Tseng M Cancers (Basel). 2025; 17(1.

PMID: 39796764 PMC: 11720667. DOI: 10.3390/cancers17010137.